mRNA vaccines: a new era in vaccine development
Shubhra Chandra,
Jennifer C Wilson,
David M. Good
и другие.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics,
Год журнала:
2024,
Номер
32(10), С. 1543 - 1564
Опубликована: Янв. 1, 2024
The
advent
of
RNA
therapy,
particularly
through
the
development
mRNA
cancer
vaccines,
has
ushered
in
a
new
era
field
oncology.
This
article
provides
concise
overview
key
principles,
recent
advancements,
and
potential
implications
vaccines
as
groundbreaking
modality
treatment.
represent
revolutionary
approach
to
combatting
by
leveraging
body's
innate
immune
system.
These
are
designed
deliver
specific
sequences
encoding
cancer-associated
antigens,
prompting
system
recognize
mount
targeted
response
against
malignant
cells.
personalized
adaptive
nature
holds
immense
for
addressing
heterogeneity
tailoring
treatments
individual
patients.
Recent
breakthroughs
exemplified
success
COVID-19
have
accelerated
their
application
platform's
versatility
allows
rapid
adaptation
vaccine
candidates
various
types,
presenting
an
agile
promising
avenue
therapeutic
intervention.
Clinical
trials
demonstrated
encouraging
results
terms
safety,
immunogenicity,
efficacy.
Pioneering
candidates,
such
BioNTech's
BNT111
Moderna's
mRNA-4157,
exhibited
outcomes
targeting
melanoma
solid
tumors,
respectively.
successes
underscore
elicit
robust
durable
anti-cancer
responses.
While
great
promise,
challenges
manufacturing
complexities
cost
considerations
need
be
addressed
widespread
adoption.
scalable
cost-effective
processes,
along
with
ongoing
clinical
research,
will
pivotal
realizing
full
vaccines.
Overall,
cutting-edge
that
promise
transforming
As
research
progresses,
refining
processes
crucial
advancing
these
from
mainstream
oncology
practice,
offering
hope
patients
fight
cancer.
Язык: Английский
Chitosan nanovectors for siRNA delivery: New horizons for nonviral gene therapy
Carbohydrate Polymers,
Год журнала:
2025,
Номер
unknown, С. 123581 - 123581
Опубликована: Апрель 1, 2025
Язык: Английский
Application of Advanced CRISPR/Cas-9 and Other Genomic Tools in RNA-Based Therapeutics
Tehreem Fatima Awan,
Muhammad Jadoon Khan
Опубликована: Янв. 1, 2025
Язык: Английский
Role of the microRNA in Prediction of the Breast Cancer
Journal of Basic Research in Medical Sciences,
Год журнала:
2025,
Номер
12(2), С. 11 - 20
Опубликована: Апрель 1, 2025
Язык: Английский
Targeting the RUNX3–miR-186-3p–DAT–IGF1R axis as a therapeutic strategy in a Parkinson’s disease model
Journal of Translational Medicine,
Год журнала:
2024,
Номер
22(1)
Опубликована: Авг. 5, 2024
With
the
increasing
age
of
population
worldwide,
incidence
rate
Parkinson's
disease
(PD)
is
annually.
Currently,
treatment
strategy
for
PD
only
improves
clinical
symptoms.
No
effective
can
slow
down
progression
disease.
In
present
study,
whole
transcriptome
sequencing
was
used
to
obtain
mRNA
and
miRNA
expression
profiles
in
a
mouse
model,
which
revealed
pathogenesis
PD.
The
transcription
factor
RUNX3
upregulated
miR-186-3p
model.
Furthermore,
high
be
targeted
inhibit
DAT
expression,
resulting
decrease
dopamine
content
dopaminergic
neurons.
Moreover,
IGF1R
prevent
activation
IGF1R–P-PI3K–P-AKT
pathway,
thus
apoptosis
neurons
by
regulating
cytochrome
c–Bax–cleaved
caspase-3
pathway.
Our
research
showed
that
RUNX3–miR-186-3p–DAT–IGF1R
axis
plays
key
role
PD,
potential
target
Язык: Английский
MicroRNAs and angiosarcoma: are there promising reports?
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Май 17, 2024
In
recent
years,
microRNAs
(miRNAs)
have
garnered
increasing
attention
for
their
potential
implications
in
cancer
pathogenesis,
functioning
either
as
oncogenes
or
tumor
suppressors.
Notably,
angiosarcoma,
along
with
various
other
cardiovascular
tumors
such
lipomas,
rhabdomyomas,
hemangiomas,
and
myxomas,
has
shown
variations
the
expression
of
specific
miRNA
subtypes.
A
substantial
body
evidence
underscores
pivotal
involvement
miRNAs
genesis
angiosarcoma
certain
tumors.
This
review
aims
to
delve
into
current
literature
on
prospective
applications
malignancies,
a
focus
angiosarcoma.
It
comprehensively
covers
diagnostic
methods,
prognostic
evaluations,
treatments
while
providing
recapitulation
angiosarcoma’s
risk
factors
molecular
an
emphasis
role
miRNAs.
These
insights
can
serve
groundwork
designing
randomized
control
trials,
ultimately
facilitating
translation
these
findings
clinical
applications.
Moving
forward,
it
is
imperative
studies
thoroughly
scrutinize
advantages
disadvantages
compared
approaches
Closing
knowledge
gaps
will
be
crucial
harnessing
full
realm
research.
Язык: Английский